To discuss the barriers to effective CAR-T therapy in acute myeloid leukemia (AML) and summarize emerging engineering strategies to overcome these challenges.
Approach:
Overview of CAR-T Cell Therapy: The review outlines the evolution of CAR-T cell therapy, highlighting the incorporation of costimulatory domains and regulatory features to enhance functional persistence, particularly relevant for AML.
Major Barriers to CAR-T Therapy in AML: The article categorizes the challenges into target-related constraints, leukemic heterogeneity, and the immunosuppressive marrow microenvironment, which collectively limit CAR-T efficacy and safety.
Key Findings:
Target selection is a central obstacle in AML CAR-T therapy due to the need for ideal targets that are uniformly expressed on AML blasts but absent from normal hematopoietic cells.
Current targets like CD33 and CD123 pose risks of damaging normal hematopoiesis, leading to significant toxicities.
Emerging targets with restricted expression may reduce toxicity but still face limitations due to leukemic heterogeneity.
Interpretation:
The challenges in AML CAR-T therapy are fundamentally different from those in B-cell malignancies.
Limitations:
The review does not provide specific clinical trial data or outcomes related to the discussed engineering strategies.
The focus on barriers may not encompass all potential solutions or advancements in CAR-T therapy for AML.
Conclusion:
Addressing the biological and immunological barriers is crucial for optimizing CAR-T therapy in AML.
